Diabetes Metab Syndr Obes. 2013 Oct 02;6:359-63. doi: 10.2147/DMSO.S51795. eCollection 2013.
Diabetes, metabolic syndrome and obesity : targets and therapy
David Scott
PMID: 24124385 PMCID: PMC3795009 DOI: 10.2147/DMSO.S51795
Diabetes is the leading cause of chronic kidney disease, and the prevalence of both diseases is rising worldwide. Treatment of type 2 diabetes is difficult in patients with chronic kidney disease because most oral antidiabetic agents are affected by renal function and their use may be contraindicated in this patient population. Antidiabetic agents that can be used in patients with type 2 diabetes and declining renal function are needed. Incretin-based therapies, such as dipeptidyl peptidase-4 inhibitors, are a recent therapeutic class of glucose-lowering agents that may offer an effective treatment option in patients with chronic kidney disease. Within the dipeptidyl peptidase-4 class, linagliptin has a unique profile with a primarily nonrenal route of elimination, requiring no dose adjustment in patients with chronic kidney disease. This communication summarizes the findings of a 1-year, randomized, double-blind, placebo-controlled study demonstrating the favorable safety and efficacy profile of linagliptin in patients with type 2 diabetes and severe renal impairment.
Keywords: DPP-4 inhibitor; incretin; renal impairment; type 2 diabetes
